Related Experiment Video
Updated: Apr 27, 2026
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Ranibizumab versus mitomycin C in primary trabeculectomy--a pilot study
Michael J Pro1, Kathryn B Freidl, Christopher J Neylan
1Department of Glaucoma, Wills Eye Hospital , Philadelphia, PA , USA .
Purpose:
The current standard adjunctive agent used in primary trabeculectomy is mitomycin C (MMC), but it is associated with well known complications. The objective of this study is to test the feasibility of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab for adjunctive use instead of MMC (0.4 mg/ml).
Materials And Methods:
A prospective, randomized open label study of 24 consecutive patients undergoing primary trabeculectomy at the Wills Eye Institute Glaucoma Service from March 2008 through February 2010 was conducted. Twenty-four eyes were included in the study and clinical outcomes were examined.
Results:
There were no significant differences in baseline demographic or clinical characteristics between the ranibizumab and MMC groups. Nine of the 12 ranibizumab patients completed the 1 year study. Three subjects required tube shunt surgery and were removed from the study. Eleven of 12 MMC patients completed the study (one underwent hip surgery and was lost to follow-up). Mean intra-ocular pressure (IOP) was significantly higher in the ranibizumab arm at 1 month (p = 0.002). Bleb extent was significantly less in the ranibizumab arm at 6 months (p = 0.006). Patients in the ranibizumab arm required more hypotensive medication at month 3 (p = 0.011).
Conclusions:
Although there was no IOP difference or difference in medication use between the two treatment groups at one year, more patients in the ranibizumab group required additional glaucoma surgery during the study period.
Insights
This study compared ranibizumab to mitomycin C for glaucoma surgery. Ranibizumab required more glaucoma surgeries, indicating it may be less effective than mitomycin C for primary trabeculectomy.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Vascular Endothelial Growth Factor Inhibitors
Background:
- Mitomycin C (MMC) is the standard adjunctive agent in primary trabeculectomy.
- MMC is associated with known complications.
- Anti-vascular endothelial growth factor (anti-VEGF) agents offer a potential alternative.
Purpose of the Study:
- To evaluate the feasibility of using the anti-VEGF agent ranibizumab as an alternative to MMC in primary trabeculectomy.
- To compare the clinical outcomes of ranibizumab versus MMC adjunctive use.
Main Methods:
- Prospective, randomized, open-label study.
- 24 consecutive patients undergoing primary trabeculectomy.
- Comparison of ranibizumab versus MMC (0.4 mg/ml) as adjunctive agents.
Main Results:
- No significant baseline differences between groups.
- Higher intra-ocular pressure (IOP) in the ranibizumab group at 1 month (p=0.002).
- Reduced bleb extent in the ranibizumab group at 6 months (p=0.006).
- Increased need for hypotensive medication in the ranibizumab group at 3 months (p=0.011).
Conclusions:
- While no significant IOP or medication differences were observed at one year, ranibizumab use led to a higher rate of subsequent glaucoma surgeries.
- Ranibizumab may be less effective than MMC in achieving long-term IOP control in primary trabeculectomy.
More Related Videos
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...